Cogent Biosciences (NASDAQ:COGT) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Cogent Biosciences from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with a $49.40 price target.
• COGT shares opened at $36.73, below the consensus target, and the company reported a quarterly loss of $0.52 per share—beating estimates by $0.03. Analysts expect a full-year loss of $2.24 per share.
• Institutional ownership has increased, with BlackRock, Deerfield Management, RTW Investments, Vanguard and Balyasny Asset Management among investors acquiring or expanding stakes.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

A number of other analysts have also weighed in on COGT. Weiss Ratings restated a "sell (d-)" rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Piper Sandler upped their price target on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an "overweight" rating in a report on Monday. HC Wainwright increased their price target on Cogent Biosciences to $55.00 and gave the company a "buy" rating in a research note on Wednesday, May 6th. Wedbush restated an "outperform" rating and set a $55.00 price objective on shares of Cogent Biosciences in a research report on Friday, May 29th. Finally, Guggenheim boosted their price objective on Cogent Biosciences from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $49.40.

Cogent Biosciences Price Performance

Cogent Biosciences stock opened at $36.73 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.57 and a current ratio of 13.57. Cogent Biosciences has a 52 week low of $11.60 and a 52 week high of $43.73. The stock has a market capitalization of $6.37 billion, a P/E ratio of -17.00 and a beta of 0.38. The stock has a fifty day moving average of $38.49 and a 200-day moving average of $36.63.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its earnings results on Monday, August 10th. The technology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. On average, sell-side analysts expect that Cogent Biosciences will post -2.24 earnings per share for the current fiscal year.

Institutional Trading of Cogent Biosciences

Institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Cogent Biosciences in the second quarter valued at $671,547,000. Deerfield Management Company L.P. lifted its holdings in Cogent Biosciences by 242.9% during the 3rd quarter. Deerfield Management Company L.P. now owns 9,053,118 shares of the technology company's stock worth $130,003,000 after buying an additional 6,412,903 shares during the period. RTW Investments LP grew its position in shares of Cogent Biosciences by 119.0% in the 4th quarter. RTW Investments LP now owns 7,592,241 shares of the technology company's stock valued at $269,676,000 after buying an additional 4,124,755 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Cogent Biosciences by 48.4% in the fourth quarter. Vanguard Group Inc. now owns 11,514,326 shares of the technology company's stock valued at $408,989,000 after buying an additional 3,756,664 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Cogent Biosciences in the third quarter valued at about $38,348,000.

Key Headlines Impacting Cogent Biosciences

Here are the key news stories impacting Cogent Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $55 price objective for COGT, signaling confidence in Cogent Biosciences’ longer-term growth prospects. HC Wainwright analyst coverage
• Positive Sentiment: The analyst expects losses to narrow significantly in 2027, forecasting quarterly EPS of $(0.50), $(0.38), $(0.26), and $(0.15), resulting in a full-year loss of $(1.28). The improving trajectory may support the stock’s valuation if Cogent’s pipeline advances as expected. Cogent Biosciences 2027 earnings estimates
• Neutral Sentiment: HC Wainwright initiated its 2027 estimates, including a $(1.28) full-year EPS forecast. These projections provide new expectations for investors but do not represent a change to the company’s operating results. Cogent Biosciences analyst estimates
• Negative Sentiment: HC Wainwright reduced its 2026 EPS forecasts, lowering Q3 estimates to $(0.59) from $(0.56), Q4 estimates to $(0.62) from $(0.57), and full-year estimates to $(2.37) from $(2.21). The revisions indicate higher expected losses in the near term and could limit upside despite the bullish rating. Cogent Biosciences 2026 earnings estimate revisions

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source